Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study

A Multi-Center Study to Evaluate the Guideline Education of Oncology Departments in Small/Middle Tier Cities and County Hospitals for Diagnosis and Treatment Improvement in Patients With Metastatic Non-small Cell Lung Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06494241

Enrollment

1000

Registered

2024-07-10

Start date

2024-11-22

Completion date

2027-11-28

Last updated

2026-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Keywords

Epidermal Growth Factor Receptor, NSCLC, Non-small cell lung cancer, Osbervational

Brief summary

To evaluate the molecular testing pattern in metastatic NSCLC patients after QIP; To evaluate the treatment pattern in metastatic NSCLC patients after QIP.

Detailed description

The primary objective of this study is to assess the implementation of standardized diagnosis and treatment practice in oncology departments of Small/Middle tier cities and County hospitals, after standardized education and implementation of lung cancer clinical practice guidelines for oncology physicians.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥18 years, at the time of signing the informed consent. * ECOG performance status 0-2. * Newly pathologic diagnosed metastatic NSCLC (clinical stage IV) or recurrent metastatic NSCLC.

Exclusion criteria

* Be participating in other intervention clinical trials. * Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements. * Previous enrolment in the other QIP study.

Design outcomes

Primary

Measure	Time frame	Description
To evaluate the molecular testing pattern in metastatic NSCLC patients after QIP	Approximately 1 month after last patient in	Molecular testing-rate for the first-line treatment: Defined as the number of participants received molecular testing for the first-line treatment divided by total participants.
To evaluate the treatment pattern in metastatic NSCLC patients after QIP	Approximately 1 month after last patient in	TKIs first-line treatment rate: Defined as TKIs first-line treatment rate in AGA positive participants.

Secondary

Measure	Time frame	Description
To evaluate the clinical outcomes in metastatic NSCLC patients after QIP	Follow up approximately 24 months after last patient in	Progression Free Survival (PFS): Defined as the time from beginning of first-line treatment to disease progression or death for any cause, whichever occurs first.
To evaluate the treatment pattern in metastatic NSCLC patients after QIP	Approximately 1 month after last patient in	1st/2nd/3rd generation EGFR-TKIs first-line treatment rate: Defined 1st/2nd/3rd generation EGFR-TKIs first-line treatment rate in EGFR positive participants.

Countries

China

Contacts

PRINCIPAL_INVESTIGATORYilong WU

Guangdong Provincial People's Hospital

Outcome results